International normalized ratio (INR) is used to monitor chronic oral anticoagulant (OA) treatment; however, it is poorly understood how this simple test reflects in vivo hemostatic reactions, culminating in thrombin generation and clot formation. We studied the process of thrombin generation using an ex vivo model, where thrombin-antithrombin (TAT) complexes are measured in blood emerging from standardized skin incisions in 55 patients (35 with venous thromboembolism [VTE] and 20 with sustained atrial fibrillation [AF]) treated with acenocoumarol (INR 2.0-3.0). In addition, in venous blood, we measured the activity of factor VIII (FVIII) and vitamin K-dependent coagulation proteins. Chronic anticoagulation led to significant reductions in maximum TAT concentrations as compared to 35 healthy controls, in maximum TAT generation rates, and in mean amount of thrombin generated. Parameters of thrombin generation did not correlate with INR or any coagulation factor measured. International normalized ratio was significantly and independently affected by the decrease in the activity of all vitamin K-dependent coagulation proteins. The strongest influence was shown for FVII. Factor VIII activity was increased in all patients studied independently of the duration of anticoagulation and did not change over time. In conclusion, in patients with VTE and AF on OA, there is no correlation between INR values and parameters of ex vivo thrombin generation. This may indicate an important role of protein C (PC) system and possibly other endothelium-dependent mechanisms in controlling hemostasis. Increased FVIII activity in patients with VTE and AF does not change significantly during anticoagulation and is probably related to the pretreatment prothrombotic state.
Coumadin derivatives (vitamin K antagonists), the oldest and the most frequently used anticoagulant drugs, reduce coagulant activity of FII, FVII, FIX, and FX by impairing their g-carboxylation. Carboxylation of anticoagulant proteins C and S is also impaired. Patients with sustained atrial fibrillation (AF) or after an episode of venous thromboembolism (VTE) require longterm oral anticoagulation (OA) to prevent systemic embolism and recurrent episodes of VTE. International normalized ratio (INR) serves as a measure of clinical efficacy and safety of such therapy. International normalized ratio is calculated from prothrombin time (PT)-a global coagulation test that has been used for a long time to monitor anticoagulant therapy. 1 For the above-mentioned (and other) clinical indications, optimal therapeutic range of OA based on INR values was established empirically. 2 Till now, there is no other precise laboratory measure that correlates anticoagulant action of coumadin derivatives with their clinical antithrombotic effects.
It was reported that patients with similar INR show significant individual variability in coagulation response to tissue factor (TF) as assessed in a whole blood coagulation model. 3 In this in vitro setting, there was no clear correlation between INR and dynamic changes of thrombin-antithrombin (TAT) complex formation, reflecting thrombin generation. The same report suggested that an increase in plasma factor VIII (FVIII) activity observed in patients on chronic OA may partially compensate for the OA-induced anti-vitamin K effect. Such findings might have clinical consequences, as elevated FVIII levels are associated with increased thrombin generation 4 and confer an independent risk of venous thromboembolic complications. 5, 6 However, in vitro systems assessing thrombin generation are strongly influenced by experimental conditions 7 and are lacking the functional influence of endothelium.
Therefore, we decided to evaluate ex vivo thrombin generation (and its parameters) at the sites of microvascular injury in patients on long-term treatment with acenocoumarol because of VTE or chronic AF. Moreover, we sought to determine possible associations between INR values and hemostatic protein activities in venous blood, with thrombin formation parameters after standardized skin microvascular injury.
Materials and Methods

Patients and Controls
We enrolled in the study 55 patients treated with acenocoumarol, including 35 patients with VTE (18 men, 17 women; aged 45.4 + 14.2 years; deep venous thrombosis and/or pulmonary embolism; confirmed by compression ultrasonography and/or chest helical computed tomography) and 20 patients with sustained AF (12 men, 8 women; aged 60.9 + 7.6 years). Thirty-five healthy individuals (20 men, 15 women; aged 39.9 + 13.8 years) served as controls. They all were in sinus rhythm, with no known episodes of VTE or any other obvious disease. All patients had at least a 6-week documented history of a stable anticoagulant effect of OA (at least 2 INR values between 2.0 and 3.0) and no known prior bleeding. Duration of oral anticoagulation ranged from 6 weeks to 10 years. Exclusion criteria were unstable angina, malignancy, diabetes mellitus, chronic renal disease (serum creatinine level >177 mmol/L), liver disease (serum aminotransferase levels >10% above the upper normal limit), congestive heart failure (NYHA (New York Heart Association) class III/IV), uncontrolled arterial hypertension, ongoing infection, connective tissue disease with the presence of lupus anticoagulant (LA) or antiphospholipid antibodies (anticardiolipin and/or anti-b 2 -GPI (glycoprotein 1)), alcohol or drug abuse, poor compliance, and concurrent treatment with agents that might affect hemostasis: statins, heparin, corticosteroids, aspirin, and other antiinflammatory nonsteroidal drugs or clopidogrel.
To elucidate the effect of OA duration on FVIII activity, we measured this variable in 15 patients (9 men, 6 women; mean age 61.9 + 4.7 years) with recently diagnosed AF during initiation of oral anticoagulation (days 0, 2, 4, 7, 30, 90, and 180). The study was approved by the local ethics committee.
Blood Sampling
Fasting venous blood was collected between 8:00 and 10:00 AM on 0.1 mol/L trisodium citrate (9:1). Plasma levels of FII, FVII, FX (1-stage PT with the use of factor depleted plasmas; Dade Behring, Germany), FVIII, and FIX (as above; based on activated partial thromboplastin time [aPTT], Dade Behring), as well as fibrinogen concentration, PT, and aPPT were measured using an automated coagulometer (BCT (Behring Coagulation Timer), Dade Behring). Commercial chromogenic assays and BCT were also used to measure antithrombin (antithrombin III-Berichrom, Dade Behring) and protein C (PC) activity (Benchrom Protein C, Dade Behring). Free protein S (PS) levels were measured by enzyme-linked immunosorbent assay (ELISA; Free Protein-S, Asserachrom, Diagnostica Stago, France). 8 Thrombin-antithrombin complexes were measured by ELISA (Enzygnost TAT, Dade Behring). Lupus anticoagulant was detected according to The International Society on Thrombosis and Haemostatis (ISTH) guidelines. 9 Anticardiolipin and anti-b2-GPI antibodies were determined by a homemade ELISA. 10, 11 The above-mentioned hemostatic parameters as well as C-reactive protein (CRP; high-sensitive, Dade Behring) concentrations were determined at the entry to the study and after 6 months.
Ex Vivo Thrombin Generation
Evaluation of ex vivo thrombin generation at sites of microvascular injury was performed according to a modified method by Kyrle et al, 12, 13 at the entry to the study and after 6 months. Briefly, a sphygmomanometer cuff that was placed on the upper arm was inflated to 40 mm Hg, then 2 standardized incisions were made on the volar aspect of the forearm using a Simplate II device (Organon Teknika, Germany), originally used to measure bleeding time. Blood oozing from the wounds was collected into heparinized capillary tubes (Baxter Deerfield, IL) every 30 seconds until bleeding stopped. The 30second samples were then immediately transferred into an commercial anticoagulant cocktail (9:1 v/v) containing sodium citrate. After centrifugation at 2000g for 20 minutes, the supernatants were collected and stored at À80 C. Concurrently, bleeding time was measured. Complexes of TAT determined in the supernatant samples were used to construct thrombin generation curve as a function of time and the following parameters were calculated: maximum TAT (TAT max) concentration, maximum rate of TAT increase (TAT rate), and the mean amount of thrombin generated. The latter was measured as the area under the thrombin generation curve, by means of the numerical integration (trapezoidal rule).
Statistical Analysis
Statistical evaluation was carried out using a personal computer and STATISTICA software (Statsoft Inc, Tulsa, OK). The response was compared between treatment groups by an analysis of variance (ANOVA) model, including factors for treatment, period (repeated-measure factor), and time (repeated-measure factor). The logarithmic transformation as a variance-stabilizing transformation was used when needed. The between-treatment differences were summarized as least square means and 95% confidence intervals using the ANOVA model. The analysis of covariance (ANCOVA) model, including factors for treatment, time, person (nested in treatment), and covariate (before treatment), was also used to adjust differential regression to the mean effects attributable to the imbalance in baseline values. The post hoc Tukey procedure was used for multiple comparisons. The level of statistical significance was set at P < .05.
Results
Clinical Characteristics
Demographic and clinical data are presented in Table 1 . Patients with AF were older than patients with VTE and healthy controls. The age of patients with VTE and controls did not differ. For this reason, patients' age was included in statistical analysis. The mean time on anticoagulation in the AF group was 4-fold longer than that in the VTE group.
Hemostatic Parameters During Anticoagulation
Mean INR was 2.53 + 0.66 in VTE, 2.29 + 0.44 in AF, and 1.01 + 0.06 in controls. All hemostatic parameters measured are presented in Table 2 .
Thrombin Generation
Thrombin generation curves were drawn based on TAT concentrations in blood issuing from sites of microvascular injury, measured in each 30-second interval. In healthy controls, mean TAT concentrations were higher in each time interval compared to OA patients, while patients with VTE and AF did not differ ( Figure 1 ). 
Maximum TAT Concentrations
The Amount of Ex Vivo Generated Thrombin
The mean amount of thrombin generated was significantly higher in healthy controls than in OA patients (P < .001 for patients with both VTE and AF). No differences were found between VTE and AF groups (Figure 2 ). There was no correlation between the length of OA treatment and the amount of generated thrombin. In addition, activity of plasma coagulation factors, free PS concentration, and INR values did not correlate with the thrombin generated.
Factor II, FVII, FIX, FX, PC, Free PS
In both groups of patients (AF and VTE), INR was in the therapeutic range and did not differ between groups. At the same time, activities of FII, FVII, FIX, FX, PC, and free PS were statistically lower than in healthy controls. There were no differences between groups treated ( Table 2) . A general linear model (GLM) for dependent variable, INR, with categorical predictor group (VTE, AF) and activity of every single coagulation factor as a continuous predictor revealed a significant influence of FII, FVII, FIX, FX, PC, and free PS on INR. Standardized regression coefficient b (regression coefficient obtained from data that have been first standardized to remove the influence of units in which the variable was measured) in ANCOVA model, describing the impact of every explanatory variable on INR, was as follows: for FIIb ¼ À.37 (P ¼ .005; observed power ¼ 0.81); for FVII-b ¼ À.59 (P < .001, observed power ¼ 0.999); for FIX-b ¼ À.58 (P < .001, observed power ¼ 0.999); for FX-b ¼ À.43 (P ¼ .001, observed power ¼ 0.924); for PC-b ¼ À.35 (P < .008, observed power ¼ 0.767); and for free PS concentration-b ¼ À.36 (P ¼ .012, observed power ¼ 0.730). The method of searching the best subset of linear predictors based on Mallow's c p index revealed that from the abovementioned explanatory variables, the best subset was formed by FVII and free PS. Standardized regression coefficients b were as follows: b ¼ À.41 (P ¼ .008, observed power ¼ 0.788) for FVII and b ¼ À.29 (P ¼ .05, observed power ¼ 0.495) for free PS concentration.
Factor VIII
Plasma activity of FVIII was significantly lower in healthy controls than in OA patients (P ¼ .009); there was no difference in FVIII activity between VTE and AF groups. There was no correlation between activity of FVIII and INR. In OA patients, a significant negative correlation was found between PC activity and FVIII (P ¼ .007; r ¼ À.036). The activity of FVIII in VTE and AF did not depend on the duration of anticoagulation time.
In an additional group of 15 patients with recently diagnosed AF, data on FVIII activity before onset of oral anticoagulation were available. Mean activity of FVIII before initiation of OA was higher in these patients with AF than in healthy controls (185.8% + 64% vs 130% + 27.1%, P ¼ .001). The activity of FVIII was relatively stable during their first 6 months of OA therapy (Figure 3 ).
Thrombin Generation After 6 Months of Stable Anticoagulation
In 20 patients (17 with VTE and 3 with AF), thrombin generation at the sites of microvascular injury was reassessed after further 6 months of anticoagulation.
There was no change in thrombin generation in the ex vivo model after these additional 6 month of OA treatment. The area under the thrombin generation curves as well as thrombin generation kinetics (TAT max; max TAT rate) were similar to the initial values. The only difference was the higher mean TAT concentration achieved in the last time point measured (240 seconds after microvascular injury; Figure 4 ).
Discussion
We have studied the process of thrombin generation ex vivo in patients on chronic anticoagulant therapy, using microvascular injury model. Major findings of our study include (1) demonstration of a significant impairment of thrombin generation in all 55 acenocoumarol-treated patients; (2) lack of correlation between this impairment and any change in a single coagulation factor or inhibitor, or an individual INR value; (3) universally increased activity of FVIII in chronically anticoagulated patients, regardless of the length of acenocoumarol treatment; and (4) demonstration, for the first time, of the absolute impact of the change in various hemostatic proteins and INR values. In the decreasing order, the strongest negative association has been shown for FVII, FIX, FX, FII, free PS concentration, and PC activity.
Little is known about in vivo thrombin generation process during chronic anticoagulant therapy. More than 10 years ago, Kyrle et al studied thrombin generation using the same model as the one used by us. 14 Their study was limited, however, to the initiation phase of coumarin therapy (first 3 days). At 48 hours after the initiation of therapy (initial dose of 20 mg of acenocoumarol followed by 12 mg on the next day), a >50% reductions in the F1þ2 and TAT levels were found in blood shed from microvascular injury. The ex vivo model has several advantages: (1) It provides insight into coagulation process initiated by TF at sites of vascular injury; and (2) It reflects hemostatic reactions in physiologic microvascular milieu, where plasma hemostatic factors, platelets and other cellular blood elements, vascular endothelium, and subendothelial structures cooperate in concert to form an adequate hemostatic plug. In this respect, our model differs from in vitro thrombin generation assays. 15, 16 The time course of TAT formation in the 30-second bleeding-time blood samples in our study was similar to that in the previous observations. 13, 17, 18 However, in contrast to in vitro models, 14, 15 in bleeding-time blood samples, it is difficult to distinguish the ''initiation,'' ''propagation,'' and ''plateau'' phases of thrombin generation.
Previously, Brummel et al 3 studied thrombin generation in 8 chronically anticoagulated patients. In a whole blood in vitro coagulation model, they demonstrated that chronic warfarin therapy impaired thrombin generation, as expressed by a decrease in TAT max, TAT rate, and fibrinopeptide A (FPA) concentration. The authors also observed substantial variations in individual TAT max and TAT rate values, as well as FPA concentrations, with no connection to the corresponding INR values. In our model, there was a significant impairment of thrombin generation in all 55 acenocoumarol-treated patients. Maximum TAT concentration, TAT rate, and mean amount of generated thrombin have all been significantly reduced (by about 40%-50% as compared to healthy individuals). Thrombin-antithrombin complexes in anticoagulated individuals have been formed about 2 times slower than in healthy controls. Thrombin formation in patients with DVT and AF did not differ and remained stable during a 6-month anticoagulant therapy. Patients with similar INRs have had various TAT profiles, consistent with the observations of Brummel et al. 3 It is difficult to quantitatively compare kinetics of thrombin generation in these 2 models. In the in vitro system, blood clots after 9.0 to 22.7 minutes, 3 with the ''initiation phase'' lasting several minutes, while bleeding after microvascular injury usually stops within 5 minutes. Keeping this in mind, it could be seen that TAT generation rates were markedly lower (approximately 100 times) in the ex vivo model than in the in vitro system used by Brummel et al, 3 while maximum TAT concentrations were decreased even further. This may be a result of the anticoagulant effect of the endothelium-bound PC system, operational in vivo but absent in majority of in vitro systems. The marked influence of PC activity and thrombomodulin presence on thrombin generation has been recently shown in another in vitro setting. 7 It could be also suspected that after injury to small skin vessels, the concentration of thrombin at which bleeding stops is much lower than the amount of thrombin produced when blood clots in the laboratory tube.
Recently, Altman et al 19 published an article on the analysis of association between thrombin generation and INR values in various patients chronically treated with oral anticoagulants (OAs). 19 They used yet another in vitro direct fully automated assay for thrombin generation. Their patients were divided into 3 groups depending on the level of anticoagulation. Although they showed significant differences in thrombin generation parameters between low-(INR ¼ 1.20-1.99), conventional-(2.00-3.49) and high-intensity (!3.50) groups, with progressive decrease in these parameters as INR increased, correlations between INR values and thrombin generation parameters across all groups were modest. It is not surprising then that in our study, where INR was kept in the narrow range between 2.0 and 3.0, such correlation could not be demonstrated at all. Already cited in vitro studies, recent analysis performed by Undas et al 20 in chronically anticoagulated patients with FV Leiden mutation as well as our current results, all point to a great flexibility in the response of an individual hemostatic system to the action of OAs. Such a response is by no means simply related to the change in the activity of any single hemostatic factor and only roughly reflected by currently used simple in vitro tests, such as PT.
In all our anticoagulated patients, FVIII activity was higher than in controls. Factor VIII activity correlated negatively only with PC activity, an observation already made by Kampuisen et al. 21 It has been suggested previously that FVIII positively correlated with the time spent on warfarin therapy, which was interpreted as a compensatory mechanism to partially correct for the vitamin K deficiency. 3 In our study, activity of FVIII did not show any association with the length of acenocoumarol therapy. Moreover, in additional 15 patients with AF, we have shown elevated FVIII activity before initiation of OA, with no further change following 6 months of acenocoumarol treatment. This observation did not support the concept of compensatory rise of FVIII activity during chronic OA treatment. It is possible that in our patients, elevated levels of FVIII were present before they started OA. Chronic nonvalvular AF is considered a hypercoagulable state in which elevated FVIII 22 together with other procoagulant mechanisms 23, 24 are operational. For obvious reasons, we were unable to measure FVIII in patients with VTE before the event and the initiation of OA.
It was suggested that thrombin generation is increased in patients with elevated FVIII:c (factor VIII coagulant activity) and VTE. 25 Using our ex vivo method, we were unable to show any association between FVIII activity and parameters of thrombin generation.
A decrease in thrombin generation induced by acenocoumarol depends exclusively on the impaired synthesis of vitamin K-dependent proteins involved in hemostasis. 2 We have analyzed complex correlations between plasma coagulation factors and INR values. Factor VII, because of its very short half life, has been found to have the strongest negative association with INR, which is in agreement with earlier studies. 26 Other factors negatively associated with INR were FIX, FX, FII, PC, and free PS concentration.
Our results (in agreement with the findings of Lind et al 26 but in contrast to that of Brummel et al 3 ) are arguing against the major influence of prothrombin depletion on INR value. They are also in agreement with the recently published results from the Netherlands. 27 In this study, the authors measured the activity of FII, FVII, and FX in patients chronically anticoagulated with acenocoumarol or phenprocoumon. They showed that all 3 factors negatively correlate with INR with the major impact of FVII, depending, however, on the time of blood sampling and the drug used. Absolute and relative impacts of remaining factors were not given.
The difference of our results from the study by Brummel et al was probably related to the small number of patients studied in the latter and/or unknown factors specific for a given in vitro system (eg, lack of the physiologic action of the endothelium-bound PC system). In the in vitro models, the velocity of the rise of TAT concentration (as a measure of thrombin generation) depends on PC, FXa, FVa, and AT activity. [28] [29] [30] In our ex vivo study, we confirm the participation of FX and PC activity (among others) as important players associated with the change in INR values. We could not confirm, however, the participation of AT; active FV was not measured in our study.
This study has several limitations. First, the number of patients studied was restricted. Certain weak associations between parameters of thrombin generation and INR values could, perhaps, become apparent with much higher number of patients studied, possibly with much broader range of INR values. However, this will only confirm that hemostatic system in an individual shows marked flexibility in response to the anticoagulant action of coumarins. There is also no reason to believe that such associations could be shown for only 1 group of patients studied (ie, AF vs VTE). At least, our results do not point to such possibility. Second, it could not be excluded that other proteins, mainly vitamin K-independent plasma hemostatic proteins (besides FVIII), which have not been measured in our study, might have an independent impact on associations analyzed in this study. However, available data do not suggest such a possibility. Finally, our system measures physiologic hemostatic reactions after mechanical injury to the skin microvessels, while OAs are meant to protect from pathological thrombosis inside the blood vessels. It is not known whether there is any difference between these reactions and whether it might influence the validity of our conclusions.
In summary, we have shown that in patients chronically and stably anticoagulated with acenocoumarol, because of VTE or AF, there is no correlation between INR values and the kinetics and amount of thrombin generated after microvascular injury. The values of thrombin generation parameters are much lower in the ex vivo method than in the in vitro system. This may indicate an important role of the vascular endothelium, PC system, and possibly other endothelium-dependent factors in controlling in vivo thrombin formation after vascular injury. Although we confirm that levels of FVIII are elevated in patients on OA, this increase is not related to the length of anticoagulant treatment and does not correlate with parameters of thrombin generation. Such an increase may be related to a pretreatment prothrombotic state. We have also shown for the first time the absolute impact of the change in various hemostatic proteins on INR values. In the decreasing order, the strongest negative association has been shown for FVII, FIX, FX, and FII as well as for free PS concentration and PC.
